



Clinical trial results:

A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus

Summary

EudraCT number	2010-024069-30
Trial protocol	NL GB HU ES DE IT BG
Global end of trial date	17 April 2014

Results information

Result version number	v1
This version publication date	02 May 2016
First version publication date	12 August 2015

Trial information

Trial identification

Sponsor protocol code	CD-IA-MEDI-545-1067
-----------------------	---------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01283139
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AstraZeneca AB
Sponsor organisation address	SE-151 85, Södertälje, Sweden,
Public contact	Gabor Illei, MD, Senior Director, Clinical development, AstraZeneca AB, IlleiG@Medimmune.com
Scientific contact	Gabor Illei, MD, Senior Director, Clinical development, AstraZeneca AB, IlleiG@Medimmune.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 April 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	17 April 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to evaluate the efficacy of sifalimumab compared to placebo in participants with chronic, moderately-to-severely active Systemic Lupus Erythematosus (SLE) with an inadequate response to standard of care (SOC) for SLE on Day 365 (Week 52).

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. Participating participant signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	31 March 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 20
Country: Number of subjects enrolled	Brazil: 45
Country: Number of subjects enrolled	Bulgaria: 16
Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	Chile: 16
Country: Number of subjects enrolled	France: 3
Country: Number of subjects enrolled	Germany: 24
Country: Number of subjects enrolled	Hungary: 20
Country: Number of subjects enrolled	India: 6
Country: Number of subjects enrolled	Italy: 9
Country: Number of subjects enrolled	Mexico: 34
Country: Number of subjects enrolled	Peru: 34
Country: Number of subjects enrolled	Philippines: 45
Country: Number of subjects enrolled	Poland: 29
Country: Number of subjects enrolled	Romania: 19

Country: Number of subjects enrolled	South Africa: 20
Country: Number of subjects enrolled	Spain: 28
Country: Number of subjects enrolled	Thailand: 12
Country: Number of subjects enrolled	United Kingdom: 13
Country: Number of subjects enrolled	United States: 38
Worldwide total number of subjects	432
EEA total number of subjects	161

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	423
From 65 to 84 years	9
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 834 participants were screened out of which 402 participants did not meet eligibility criteria and were considered screen failures, and 432 participants were randomized into the study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Placebo matching to sifalimumab administered by intravenous infusion at a fixed dose of every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Placebo matching to sifalimumab administered by intravenous infusion at a fixed dose of every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.

Arm title	Sifalimumab 200 milligram (mg)
------------------	--------------------------------

Arm description:

Sifalimumab 200 mg administered by intravenous infusion every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.

Arm type	Experimental
Investigational medicinal product name	Sifalimumab 200 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Sifalimumab 200 mg administered by intravenous infusion every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.

Arm title	Sifalimumab 600 mg
------------------	--------------------

Arm description:

Sifalimumab 600 mg administered by intravenous infusion every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Sifalimumab 600 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Sifalimumab 600 mg administered by intravenous infusion every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.

Arm title	Sifalimumab 1,200 mg
------------------	----------------------

Arm description:

Sifalimumab 1,200 mg administered by intravenous infusion every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.

Arm type	Experimental
Investigational medicinal product name	Sifalimumab 1,200 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Sifalimumab 1,200 mg administered by intravenous infusion every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.

Number of subjects in period 1	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg
Started	108	108	109
Completed	91	90	91
Not completed	17	18	18
Adverse event, serious fatal	2	-	2
Consent withdrawn by subject	8	8	6
Pregnancy	-	1	1
Missed follow-up visit	-	1	2
Participant randomized in error	-	-	1
Early termination due to AE/SAE	1	1	-
Lost to follow-up	5	2	3
Lack of efficacy	1	2	2
Participant's refusal to continue	-	3	1

Number of subjects in period 1	Sifalimumab 1,200 mg
Started	107
Completed	92
Not completed	15
Adverse event, serious fatal	2
Consent withdrawn by subject	8
Pregnancy	-

Missed follow-up visit	2
Participant randomized in error	-
Early termination due to AE/SAE	-
Lost to follow-up	1
Lack of efficacy	1
Participant's refusal to continue	1

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description: Placebo matching to sifalimumab administered by intravenous infusion at a fixed dose of every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.	
Reporting group title	Sifalimumab 200 milligram (mg)
Reporting group description: Sifalimumab 200 mg administered by intravenous infusion every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.	
Reporting group title	Sifalimumab 600 mg
Reporting group description: Sifalimumab 600 mg administered by intravenous infusion every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.	
Reporting group title	Sifalimumab 1,200 mg
Reporting group description: Sifalimumab 1,200 mg administered by intravenous infusion every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.	

Reporting group values	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg
Number of subjects	108	108	109
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age Continuous Units: years			
arithmetic mean standard deviation	38.4 ± 12.3	39.9 ± 11.4	40.1 ± 11.3
Gender, Male/Female Units: participants			
Female	101	103	98
Male	7	5	11

Reporting group values	Sifalimumab 1,200 mg	Total	
Number of subjects	107	432	

Age categorical Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age Continuous Units: years			
arithmetic mean	39.4		
standard deviation	± 12.1	-	
Gender, Male/Female Units: participants			
Female	97	399	
Male	10	33	

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: Placebo matching to sifalimumab administered by intravenous infusion at a fixed dose of every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.	
Reporting group title	Sifalimumab 200 milligram (mg)
Reporting group description: Sifalimumab 200 mg administered by intravenous infusion every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.	
Reporting group title	Sifalimumab 600 mg
Reporting group description: Sifalimumab 600 mg administered by intravenous infusion every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.	
Reporting group title	Sifalimumab 1,200 mg
Reporting group description: Sifalimumab 1,200 mg administered by intravenous infusion every 2 weeks (14 days) for the first 3 doses (Days 1, 15, and 29) and then every 4 weeks (28 days) thereafter for 11 doses for a total of 14 doses.	
Subject analysis set title	Modified Intent-to-treat (mITT) Population
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: The mITT population included all randomized participants who received any investigational product and had a baseline primary efficacy measurement.	
Subject analysis set title	Safety Population
Subject analysis set type	Safety analysis
Subject analysis set description: The safety population included all participants who received any investigational product.	

Primary: Percentage of Participants Achieving a Response in Systemic Lupus Erythematosus Responder Index 4 (SRI [4])

End point title	Percentage of Participants Achieving a Response in Systemic Lupus Erythematosus Responder Index 4 (SRI [4])
End point description: SRI (4) responder is defined as: 1) a reduction in baseline Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) disease activity score of greater than or equal to (\geq) 4 points (with increased deoxyribonucleic acid [DNA] binding item of SLEDAI-2K score based on the ANA Multi-Lyte® ANA-II Plus Test System); 2) no worsening in Physician Global Assessment (MDGA) (worsening is defined as an increase of ≥ 0.3 from baseline on a 0-3 visual analogue scale) and 3) no worsening in British Isles Lupus Assessment Group (BILAG-2004) (worsening is defined as at least 1 new 'A' score or 2 new 'B' scores on the BILAG-2004 compared with baseline). The modified intent-to-treat (mITT) population included all randomized participants who received any investigational product and had a baseline primary efficacy measurement.	
End point type	Primary
End point timeframe: Day 365	

End point values	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg	Sifalimumab 1,200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	108	108	108	107
Units: percentage of participants				
number (not applicable)	45.4	58.3	56.5	59.8

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Placebo v Sifalimumab 200 milligram (mg)
Number of subjects included in analysis	216
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.057
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.71
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.03
upper limit	2.71

Statistical analysis title	Statistical analysis 3
Comparison groups	Placebo v Sifalimumab 1,200 mg
Number of subjects included in analysis	215
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.031
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.84
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.16
upper limit	2.94

Statistical analysis title	Statistical analysis 2
Comparison groups	Placebo v Sifalimumab 600 mg

Number of subjects included in analysis	216
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.094
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.01
upper limit	2.54

Primary: Percentage of Participants Achieving a Positive Response in SRI (4) in 4-Gene Interferon Test High Participants

End point title	Percentage of Participants Achieving a Positive Response in SRI (4) in 4-Gene Interferon Test High Participants
End point description:	SRI (4) responder is defined as: 1) a reduction in baseline SLEDAI-2K disease activity score of ≥ 4 points (with increased DNA binding item of SLEDAI-2K score based on the ANA Multi-Lyte® ANA-II Plus Test System); 2) no worsening in Physician Global Assessment (MDGA) (worsening is defined as an increase of ≥ 0.3 from baseline on a 0-3 visual analogue scale) and 3) no worsening in BILAG-2004 (worsening is defined as at least 1 new 'A' score or 2 new 'B' scores on the BILAG-2004 compared with baseline). The mITT population included all randomized participants who received any investigational product and had a baseline primary efficacy measurement.
End point type	Primary
End point timeframe:	Day 365

End point values	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg	Sifalimumab 1,200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	88	87	88	87
Units: percentage of participants				
number (not applicable)	42	57.5	50	57.5

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Placebo v Sifalimumab 200 milligram (mg)

Number of subjects included in analysis	175
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.042
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.88
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.13
upper limit	3.14

Statistical analysis title	Statistical analysis 2
Comparison groups	Placebo v Sifalimumab 600 mg
Number of subjects included in analysis	176
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.264
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.41
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.85
upper limit	2.35

Statistical analysis title	Statistical analysis 3
Comparison groups	Placebo v Sifalimumab 1,200 mg
Number of subjects included in analysis	175
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.038
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.91
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.14
upper limit	3.19

Secondary: Percentage of Participants on Greater Than or Equal to 10 mg/day Oral

Prednisone (or Equivalent) at Baseline who Were Able to Reduce to Less Than or Equal to (\leq) 7.5 mg/day

End point title	Percentage of Participants on Greater Than or Equal to 10 mg/day Oral Prednisone (or Equivalent) at Baseline who Were Able to Reduce to Less Than or Equal to (\leq) 7.5 mg/day
-----------------	---

End point description:

Percentage of participants on ≥ 10 mg/day oral corticosteroids (OCS) at baseline who were able to taper it to ≤ 7.5 mg/day by Day 365 were recorded. The mITT population included all randomized participants who received any investigational product and had a baseline primary efficacy measurement. Here, "N" signifies number of participants analyzed on ≥ 10 mg/day oral prednisone (or equivalent) at baseline.

End point type	Secondary
End point timeframe:	
Day 365	

End point values	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg	Sifalimumab 1,200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	61	53	65
Units: percentage of participants				
number (not applicable)				
Reduce OCS to ≤ 7.5 mg/day: Yes	6.5	8.2	9.4	6.2
Reduce OCS to ≤ 7.5 mg/day: No	93.5	91.8	90.6	93.8

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Placebo v Sifalimumab 200 milligram (mg)
Number of subjects included in analysis	123
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.808
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.19
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.37
upper limit	3.81

Statistical analysis title	Statistical analysis 2
Comparison groups	Placebo v Sifalimumab 600 mg

Number of subjects included in analysis	115
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.598
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.45
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.45
upper limit	4.66

Statistical analysis title	Statistical analysis 3
Comparison groups	Placebo v Sifalimumab 1,200 mg
Number of subjects included in analysis	127
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.884
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	0.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.27
upper limit	3.02

Secondary: Percentage of Participants with a Cutaneous Lupus Erythematosus Disease Activity and Severity Index (CLASI) Activity Score Greater Than or Equal to (\geq) 10 at Baseline Who Achieved a \geq 4-point Reduction

End point title	Percentage of Participants with a Cutaneous Lupus Erythematosus Disease Activity and Severity Index (CLASI) Activity Score Greater Than or Equal to (\geq) 10 at Baseline Who Achieved a \geq 4-point Reduction
-----------------	---

End point description:

The CLASI consists of two scores, the first summarizes the activity of the disease while the second is a measure of the damage done by the disease. Activity is scored on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. Damage is scored in terms of dyspigmentation and scarring, including scarring alopecia. The percentage of participants with a CLASI activity score ≥ 10 at baseline who achieved a clinically significant (≥ 4 -point) reduction at Day 365 were reported. The mITT population included all randomized participants who received any investigational product and had a baseline primary efficacy measurement. Here, "N" signifies number of participants analyzed with a CLASI activity score ≥ 10 at baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 365

End point values	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg	Sifalimumab 1,200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	33	33	26
Units: percentage of participants number (not applicable)				
Achieved ≥ 4 -point reduction: Yes	48.6	72.7	57.6	73.1
Achieved ≥ 4 -point reduction: No	51.4	27.3	42.4	26.9

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Placebo v Sifalimumab 200 milligram (mg)
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.044
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	2.92
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.22
upper limit	7.01

Statistical analysis title	Statistical analysis 2
Comparison groups	Placebo v Sifalimumab 600 mg
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.498
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.62
upper limit	3.19

Statistical analysis title	Statistical analysis 3
Comparison groups	Placebo v Sifalimumab 1,200 mg
Number of subjects included in analysis	61
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.049
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	3.03
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.2
upper limit	7.68

Secondary: Percentage of Participants who Achieved a Greater Than 3-Point Improvement in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale

End point title	Percentage of Participants who Achieved a Greater Than 3-Point Improvement in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale
-----------------	--

End point description:

FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). The mITT population included all randomized participants who received any investigational product and had a baseline primary efficacy measurement. Here, "N" signifies number of participants analyzed with a FACIT-fatigue score <49 at baseline.

End point type	Secondary
End point timeframe:	
Day 365	

End point values	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg	Sifalimumab 1,200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	105	105	102	101
Units: percentage of participants				
number (not applicable)				
Achieved > 3-point improvement: Yes	30.5	38.1	42.2	35.6
Achieved > 3-point improvement: No	69.5	61.9	57.8	64.4

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Placebo v Sifalimumab 200 milligram (mg)
Number of subjects included in analysis	210
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.27
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.39
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.85
upper limit	2.25

Statistical analysis title	Statistical analysis 2
Comparison groups	Placebo v Sifalimumab 600 mg
Number of subjects included in analysis	207
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.077
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.69
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.04
upper limit	2.74

Statistical analysis title	Statistical analysis 3
Comparison groups	Placebo v Sifalimumab 1,200 mg

Number of subjects included in analysis	206
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.453
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.25
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.76
upper limit	2.05

Secondary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)

End point title	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)
-----------------	---

End point description:

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent defined as events present at baseline that worsened in intensity after administration of investigational product or events absent at baseline that emerged after administration of investigational product, for the period extending until the end of participant participation in the study. The safety population included all participants who received any investigational product.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 up to Week 74

End point values	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg	Sifalimumab 1,200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	108	108	108	107
Units: participants				
TEAE	94	97	97	93
TESAE	19	16	22	21

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAEs)

End point title	Number of Participants with Abnormal Clinical Laboratory
-----------------	--

End point description:

Laboratory investigations included hematology, serum chemistries and urinalysis parameters. Participants with clinically significant abnormalities in these laboratory investigations recorded as TEAEs were reported. The safety population included all participants who received any investigational product.

End point type Secondary

End point timeframe:

Day 1 up to Week 61

End point values	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg	Sifalimumab 1,200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	108	108	108	107
Units: participants				
Anaemia	1	4	4	2
White blood cell count increased	3	1	2	3
Neutrophil count increased	3	1	2	2
Iron deficiency anaemia	1	2	0	2
Haemoglobin decreased	0	1	0	1
Lymphocyte count decreased	2	1	1	0
White blood cell count decreased	1	0	1	1
Autoimmune haemolytic anaemia	1	1	0	0
Eosinophilia	0	0	0	1
Haematocrit increased	0	0	1	0
Haemoglobin increased	0	0	1	0
Leukopenia	0	1	0	0
Lymphopenia	1	1	0	0
Neutropenia	3	0	0	1
Neutrophil count decreased	1	0	0	1
Platelet count increased	0	0	1	0
Red blood cell count decreased	0	0	0	1
Thrombocytopenia	0	1	0	0
Platelet count decreased	2	0	0	0
Monocyte count increased	1	0	0	0
Hypokalaemia	4	1	4	5
Alanine aminotransferase increased	5	1	1	3
Gamma-glutamyltransferase increased	5	0	1	4
Hypertriglyceridaemia	2	1	1	3
Dyslipidaemia	2	0	2	2
Hepatic enzyme increased	2	2	2	0
Aspartate aminotransferase increased	2	1	0	2
Blood creatine phosphokinase increased	2	0	2	0
Blood creatinine increased	0	1	0	1
Blood glucose increased	1	0	0	2
Hyperglycaemia	1	0	0	2
Transaminases increased	1	0	1	1
Blood potassium decreased	0	1	1	0
Low density lipoprotein increased	0	1	1	0

Blood albumin decreased	0	0	1	0
Blood alkaline phosphatase decreased	1	0	0	1
Blood calcium increased	1	0	1	0
Blood cholesterol increased	0	0	1	0
Blood homocysteine increased	0	0	1	0
Liver function test abnormal	1	0	1	0
Hyperlipidaemia	0	0	0	1
Hypoalbuminaemia	2	0	1	0
Hypoglycaemia	0	0	0	1
Blood bilirubin increased	1	0	0	0
Hypocalcaemia	1	0	0	0
Blood triglycerides increased	1	0	1	0
Hyperbilirubinaemia	0	0	1	0
Hypertransaminasaemia	0	0	1	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)

End point title	Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)
-----------------	--

End point description:

Vital sign assessments included blood pressure, pulse rate, temperature, weight and respiratory rate. Vital signs abnormalities recorded as TEAEs were reported. The safety population included all participants who received any investigational product.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 up to Week 61

End point values	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg	Sifalimumab 1,200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	108	108	108	107
Units: participants				
Pyrexia	3	2	6	7
Hypertension	7	4	5	4
Weight increased	0	1	2	2
Blood pressure increased	1	2	1	0
Chills	1	2	0	1
Hypertensive crisis	0	0	0	1
Orthostatic hypotension	1	0	0	1
Weight decreased	1	0	0	1
Hypotension	1	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Abnormal Electrocardiogram (ECG) Findings Reported as TEAEs

End point title	Number of Participants With Abnormal Electrocardiogram (ECG) Findings Reported as TEAEs
-----------------	---

End point description:

The 12-lead ECG data were summarized and evaluated. Number of participants with clinically significant abnormal ECG findings as assessed by cardiologist were recorded and reported as TEAEs. The safety population included all participants who received any investigational product.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 up to Week 56

End point values	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg	Sifalimumab 1,200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	108	108	108	107
Units: participants	2	0	1	0

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Day 1 up to Week 74

Adverse event reporting additional description:

TEAE defined as events present at baseline that worsened in intensity after administration of investigational product or events absent at baseline that emerged after administration of investigational product, for the period extending until the end of participant participation in the study.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.0
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo matching to sifalimumab administered intravenously for 48 weeks (Day 337).

Reporting group title	Sifalimumab 200 milligram (mg)
-----------------------	--------------------------------

Reporting group description:

Sifalimumab 200 milligram (mg) administered intravenously for 48 weeks (Day 337).

Reporting group title	Sifalimumab 600 mg
-----------------------	--------------------

Reporting group description:

Sifalimumab 600 mg administered intravenously for 48 weeks (Day 337).

Reporting group title	Sifalimumab 1,200 mg
-----------------------	----------------------

Reporting group description:

Sifalimumab 1,200 mg administered intravenously for 48 weeks (Day 337).

Serious adverse events	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	19 / 108 (17.59%)	16 / 108 (14.81%)	22 / 108 (20.37%)
number of deaths (all causes)	2	0	2
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung neoplasm malignant			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic limb pain			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery thrombosis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral embolism			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Abortion induced			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abortion spontaneous incomplete			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ectopic pregnancy			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cervical dysplasia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal polyp			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction alternative assessment type: Systematic			

subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meniscus injury alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle rupture alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stab wound alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	2 / 108 (1.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris alternative assessment type: Systematic			

subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardio-respiratory arrest			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Mitral valve incompetence			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Nervous system disorders			
Ischaemic stroke			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Simple partial seizures			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasculitis cerebral alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Ascites alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum oesophageal alternative assessment type: Systematic			

subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis haemorrhagic			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intussusception			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Irritable bowel syndrome			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lip ulceration			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salivary gland calculus			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Small intestinal perforation alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tongue oedema alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Skin ulcer alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal failure acute alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flank pain alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			

alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	1 / 108 (0.93%)	2 / 108 (1.85%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic lupus erythematosus			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 108 (2.78%)	4 / 108 (3.70%)	7 / 108 (6.48%)
occurrences causally related to treatment / all	0 / 3	0 / 4	1 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	1 / 108 (0.93%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Corneal infection			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 108 (0.00%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis viral			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis bacterial			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epiglottitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infectious colitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lobar pneumonia			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ludwig angina			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis bacterial			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ophthalmic herpes zoster			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parotitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	1 / 108 (0.93%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Progressive multifocal leukoencephalopathy			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 108 (0.93%)	2 / 108 (1.85%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic embolus alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock alternative assessment type: Systematic			
subjects affected / exposed	2 / 108 (1.85%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 2	0 / 0	0 / 0
Soft tissue infection alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Urinary tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Sifalimumab 1,200 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	21 / 107 (19.63%)		
number of deaths (all causes)	2		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung neoplasm malignant			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Hypertension			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ischaemic limb pain			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral artery thrombosis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral embolism			

alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Abortion induced			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abortion spontaneous incomplete			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ectopic pregnancy			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Cervical dysplasia			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal			

disorders				
Asthma				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 107 (0.93%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Epistaxis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Laryngeal polyp				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary embolism				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary hypertension				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Injury, poisoning and procedural complications				
Fall				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fracture				

alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Head injury				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Humerus fracture				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infusion related reaction				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Meniscus injury				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Muscle rupture				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Spinal compression fracture				
alternative assessment type: Systematic				

subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stab wound			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardiac disorders			
Acute myocardial infarction			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Angina pectoris			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac arrest			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardio-respiratory arrest			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mitral valve incompetence			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Ischaemic stroke			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Simple partial seizures			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transient ischaemic attack			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vasculitis cerebral			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
alternative assessment type: Systematic			

subjects affected / exposed	2 / 107 (1.87%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Ascites			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diverticulum oesophageal			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastritis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastritis haemorrhagic			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intussusception			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Irritable bowel syndrome			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lip ulceration			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Salivary gland calculus			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small intestinal perforation			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tongue oedema			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Skin ulcer			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal failure acute			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Flank pain			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Foot deformity			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Osteonecrosis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Systemic lupus erythematosus			
alternative assessment type: Systematic			

subjects affected / exposed	3 / 107 (2.80%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendicitis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 107 (0.93%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Bronchitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Corneal infection			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Encephalitis viral			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 107 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enterocolitis bacterial			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Epiglottitis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Erysipelas				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Herpes zoster				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 107 (0.93%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infectious colitis				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 107 (0.93%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Influenza				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Lobar pneumonia alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 107 (0.93%) 0 / 1 0 / 0			
Lower respiratory tract infection alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 107 (0.93%) 0 / 1 0 / 0			
Ludwig angina alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 107 (0.00%) 0 / 0 0 / 0			
Meningitis bacterial alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 107 (0.93%) 0 / 1 0 / 0			
Ophthalmic herpes zoster alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 107 (0.93%) 0 / 1 0 / 0			
Parotitis alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 107 (0.93%) 0 / 1 0 / 0			
Peritonitis alternative assessment type: Systematic				

subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
alternative assessment type: Systematic				
subjects affected / exposed	2 / 107 (1.87%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Progressive multifocal leukoencephalopathy				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis acute				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory tract infection				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
alternative assessment type: Systematic				

subjects affected / exposed	1 / 107 (0.93%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Septic embolus				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Septic shock				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Soft tissue infection				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract infection				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 107 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	Placebo	Sifalimumab 200 milligram (mg)	Sifalimumab 600 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	94 / 108 (87.04%)	97 / 108 (89.81%)	97 / 108 (89.81%)
Vascular disorders			
Hypertension			
alternative assessment type: Systematic			
subjects affected / exposed	7 / 108 (6.48%)	4 / 108 (3.70%)	5 / 108 (4.63%)
occurrences (all)	8	4	5
General disorders and administration site conditions			
Pyrexia			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 108 (2.78%)	2 / 108 (1.85%)	6 / 108 (5.56%)
occurrences (all)	4	3	10
Respiratory, thoracic and mediastinal disorders			
Cough			
alternative assessment type: Systematic			
subjects affected / exposed	7 / 108 (6.48%)	7 / 108 (6.48%)	5 / 108 (4.63%)
occurrences (all)	7	7	5
Epistaxis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	4 / 108 (3.70%)	2 / 108 (1.85%)
occurrences (all)	1	4	3
Oropharyngeal pain			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 108 (3.70%)	4 / 108 (3.70%)	1 / 108 (0.93%)
occurrences (all)	5	4	1
Psychiatric disorders			
Anxiety			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 108 (2.78%)	6 / 108 (5.56%)	2 / 108 (1.85%)
occurrences (all)	3	6	2
Insomnia			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 108 (3.70%)	7 / 108 (6.48%)	3 / 108 (2.78%)
occurrences (all)	4	8	3

Investigations			
Alanine aminotransferase increased			
alternative assessment type:			
Systematic			
subjects affected / exposed	5 / 108 (4.63%)	1 / 108 (0.93%)	1 / 108 (0.93%)
occurrences (all)	7	1	1
Gamma-glutamyltransferase increased			
alternative assessment type:			
Systematic			
subjects affected / exposed	5 / 108 (4.63%)	0 / 108 (0.00%)	1 / 108 (0.93%)
occurrences (all)	7	0	2
White blood cell count increased			
alternative assessment type:			
Systematic			
subjects affected / exposed	3 / 108 (2.78%)	1 / 108 (0.93%)	2 / 108 (1.85%)
occurrences (all)	4	1	4
Injury, poisoning and procedural complications			
Contusion			
alternative assessment type:			
Systematic			
subjects affected / exposed	3 / 108 (2.78%)	2 / 108 (1.85%)	3 / 108 (2.78%)
occurrences (all)	4	2	3
Infusion related reaction			
alternative assessment type:			
Systematic			
subjects affected / exposed	5 / 108 (4.63%)	8 / 108 (7.41%)	7 / 108 (6.48%)
occurrences (all)	10	17	9
Nervous system disorders			
Dizziness			
alternative assessment type:			
Systematic			
subjects affected / exposed	5 / 108 (4.63%)	5 / 108 (4.63%)	2 / 108 (1.85%)
occurrences (all)	5	6	2
Headache			
alternative assessment type:			
Systematic			
subjects affected / exposed	15 / 108 (13.89%)	16 / 108 (14.81%)	15 / 108 (13.89%)
occurrences (all)	24	18	37
Blood and lymphatic system disorders			
Anaemia			
alternative assessment type:			
Systematic			

subjects affected / exposed occurrences (all)	1 / 108 (0.93%) 1	3 / 108 (2.78%) 3	4 / 108 (3.70%) 4
Gastrointestinal disorders			
Abdominal pain			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 108 (1.85%)	0 / 108 (0.00%)	6 / 108 (5.56%)
occurrences (all)	2	0	7
Abdominal pain upper			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 108 (3.70%)	1 / 108 (0.93%)	5 / 108 (4.63%)
occurrences (all)	5	1	5
Constipation			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 108 (1.85%)	1 / 108 (0.93%)	2 / 108 (1.85%)
occurrences (all)	2	1	2
Diarrhoea			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 108 (7.41%)	7 / 108 (6.48%)	9 / 108 (8.33%)
occurrences (all)	9	7	9
Dyspepsia			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 108 (2.78%)	3 / 108 (2.78%)	1 / 108 (0.93%)
occurrences (all)	3	3	1
Gastritis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 108 (0.00%)	3 / 108 (2.78%)	3 / 108 (2.78%)
occurrences (all)	0	3	5
Nausea			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 108 (7.41%)	4 / 108 (3.70%)	7 / 108 (6.48%)
occurrences (all)	12	5	11
Vomiting			
alternative assessment type: Systematic			

subjects affected / exposed occurrences (all)	5 / 108 (4.63%) 5	1 / 108 (0.93%) 1	6 / 108 (5.56%) 8
Skin and subcutaneous tissue disorders			
Rash			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	1 / 108 (0.93%)	2 / 108 (1.85%)
occurrences (all)	1	1	2
Pruritus			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 108 (1.85%)	7 / 108 (6.48%)	3 / 108 (2.78%)
occurrences (all)	2	8	3
Musculoskeletal and connective tissue disorders			
Arthralgia			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 108 (2.78%)	2 / 108 (1.85%)	9 / 108 (8.33%)
occurrences (all)	6	3	11
Back pain			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 108 (2.78%)	3 / 108 (2.78%)	8 / 108 (7.41%)
occurrences (all)	3	3	8
Systemic lupus erythematosus			
alternative assessment type: Systematic			
subjects affected / exposed	35 / 108 (32.41%)	34 / 108 (31.48%)	31 / 108 (28.70%)
occurrences (all)	56	42	46
Infections and infestations			
Bronchitis			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 108 (7.41%)	11 / 108 (10.19%)	4 / 108 (3.70%)
occurrences (all)	8	15	7
Conjunctivitis			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 108 (3.70%)	4 / 108 (3.70%)	1 / 108 (0.93%)
occurrences (all)	5	5	1
Gastroenteritis			
alternative assessment type: Systematic			

subjects affected / exposed	5 / 108 (4.63%)	5 / 108 (4.63%)	5 / 108 (4.63%)
occurrences (all)	6	6	6
Herpes zoster			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 108 (0.93%)	5 / 108 (4.63%)	4 / 108 (3.70%)
occurrences (all)	1	6	4
Influenza			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 108 (3.70%)	3 / 108 (2.78%)	1 / 108 (0.93%)
occurrences (all)	4	3	1
Nasopharyngitis			
alternative assessment type: Systematic			
subjects affected / exposed	10 / 108 (9.26%)	12 / 108 (11.11%)	13 / 108 (12.04%)
occurrences (all)	17	14	15
Oral herpes			
alternative assessment type: Systematic			
subjects affected / exposed	5 / 108 (4.63%)	3 / 108 (2.78%)	3 / 108 (2.78%)
occurrences (all)	6	7	4
Pharyngitis			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 108 (3.70%)	3 / 108 (2.78%)	6 / 108 (5.56%)
occurrences (all)	5	3	9
Respiratory tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 108 (2.78%)	1 / 108 (0.93%)	3 / 108 (2.78%)
occurrences (all)	5	1	3
Sinusitis			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 108 (2.78%)	2 / 108 (1.85%)	4 / 108 (3.70%)
occurrences (all)	3	2	4
Upper respiratory tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	9 / 108 (8.33%)	10 / 108 (9.26%)	17 / 108 (15.74%)
occurrences (all)	12	16	27

Urinary tract infection alternative assessment type: Systematic subjects affected / exposed occurrences (all)	14 / 108 (12.96%) 19	22 / 108 (20.37%) 25	17 / 108 (15.74%) 22
Metabolism and nutrition disorders Diabetes mellitus alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 108 (1.85%) 2	2 / 108 (1.85%) 2	3 / 108 (2.78%) 4
Hypokalaemia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	4 / 108 (3.70%) 5	1 / 108 (0.93%) 1	4 / 108 (3.70%) 5

Non-serious adverse events	Sifalimumab 1,200 mg		
Total subjects affected by non-serious adverse events subjects affected / exposed	93 / 107 (86.92%)		
Vascular disorders Hypertension alternative assessment type: Systematic subjects affected / exposed occurrences (all)	3 / 107 (2.80%) 3		
General disorders and administration site conditions Pyrexia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	7 / 107 (6.54%) 10		
Respiratory, thoracic and mediastinal disorders Cough alternative assessment type: Systematic subjects affected / exposed occurrences (all)	6 / 107 (5.61%) 6		
Epistaxis alternative assessment type: Systematic			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Oropharyngeal pain</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 107 (1.87%)</p> <p>2</p> <p>0 / 107 (0.00%)</p> <p>0</p>		
<p>Psychiatric disorders</p> <p>Anxiety</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Insomnia</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>7 / 107 (6.54%)</p> <p>8</p> <p>1 / 107 (0.93%)</p> <p>1</p>		
<p>Investigations</p> <p>Alanine aminotransferase increased</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Gamma-glutamyltransferase increased</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>White blood cell count increased</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 107 (2.80%)</p> <p>5</p> <p>4 / 107 (3.74%)</p> <p>5</p> <p>3 / 107 (2.80%)</p> <p>5</p>		
<p>Injury, poisoning and procedural complications</p> <p>Contusion</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Infusion related reaction</p> <p>alternative assessment type:</p>	<p>1 / 107 (0.93%)</p> <p>1</p>		

Systematic subjects affected / exposed occurrences (all)	5 / 107 (4.67%) 10		
Nervous system disorders Dizziness alternative assessment type: Systematic subjects affected / exposed occurrences (all) Headache alternative assessment type: Systematic subjects affected / exposed occurrences (all)	5 / 107 (4.67%) 5 12 / 107 (11.21%) 13		
Blood and lymphatic system disorders Anaemia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1		
Gastrointestinal disorders Abdominal pain alternative assessment type: Systematic subjects affected / exposed occurrences (all) Abdominal pain upper alternative assessment type: Systematic subjects affected / exposed occurrences (all) Constipation alternative assessment type: Systematic subjects affected / exposed occurrences (all) Diarrhoea alternative assessment type: Systematic subjects affected / exposed occurrences (all) Dyspepsia alternative assessment type:	4 / 107 (3.74%) 4 4 / 107 (3.74%) 4 5 / 107 (4.67%) 5 5 / 107 (4.67%) 5		

Systematic subjects affected / exposed occurrences (all)	4 / 107 (3.74%) 4		
Gastritis alternative assessment type: Systematic subjects affected / exposed occurrences (all)	3 / 107 (2.80%) 3		
Nausea alternative assessment type: Systematic subjects affected / exposed occurrences (all)	5 / 107 (4.67%) 7		
Vomiting alternative assessment type: Systematic subjects affected / exposed occurrences (all)	3 / 107 (2.80%) 3		
Skin and subcutaneous tissue disorders Rash alternative assessment type: Systematic subjects affected / exposed occurrences (all)	6 / 107 (5.61%) 6		
Pruritus alternative assessment type: Systematic subjects affected / exposed occurrences (all)	5 / 107 (4.67%) 8		
Musculoskeletal and connective tissue disorders Arthralgia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	5 / 107 (4.67%) 5		
Back pain alternative assessment type: Systematic subjects affected / exposed occurrences (all)	5 / 107 (4.67%) 5		
Systemic lupus erythematosus alternative assessment type: Systematic			

subjects affected / exposed	26 / 107 (24.30%)		
occurrences (all)	46		
Infections and infestations			
Bronchitis			
alternative assessment type:			
Systematic			
subjects affected / exposed	15 / 107 (14.02%)		
occurrences (all)	20		
Conjunctivitis			
alternative assessment type:			
Systematic			
subjects affected / exposed	2 / 107 (1.87%)		
occurrences (all)	2		
Gastroenteritis			
alternative assessment type:			
Systematic			
subjects affected / exposed	4 / 107 (3.74%)		
occurrences (all)	4		
Herpes zoster			
alternative assessment type:			
Systematic			
subjects affected / exposed	8 / 107 (7.48%)		
occurrences (all)	8		
Influenza			
alternative assessment type:			
Systematic			
subjects affected / exposed	5 / 107 (4.67%)		
occurrences (all)	5		
Nasopharyngitis			
alternative assessment type:			
Systematic			
subjects affected / exposed	9 / 107 (8.41%)		
occurrences (all)	12		
Oral herpes			
alternative assessment type:			
Systematic			
subjects affected / exposed	4 / 107 (3.74%)		
occurrences (all)	5		
Pharyngitis			
alternative assessment type:			
Systematic			

subjects affected / exposed	12 / 107 (11.21%)		
occurrences (all)	12		
Respiratory tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 107 (2.80%)		
occurrences (all)	4		
Sinusitis			
alternative assessment type: Systematic			
subjects affected / exposed	5 / 107 (4.67%)		
occurrences (all)	7		
Upper respiratory tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	15 / 107 (14.02%)		
occurrences (all)	23		
Urinary tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	18 / 107 (16.82%)		
occurrences (all)	25		
Metabolism and nutrition disorders			
Diabetes mellitus			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 107 (1.87%)		
occurrences (all)	2		
Hypokalaemia			
alternative assessment type: Systematic			
subjects affected / exposed	5 / 107 (4.67%)		
occurrences (all)	7		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 June 2011	The overall reason for the amendment was to include the following changes: Changes in eligibility criteria. Added instruction for participants who entered the study with indeterminate QuantiFERON-TB Gold blood test results. Changes in the hepatitis B virus deoxyribonucleic acid (HBV DNA) level required to qualify and remain in the study from " ≤ 300 copies/mL" to "HBV DNA detected by reflex testing by the central lab at screening or at any time for the duration of the study." Also specified that the frequency of HBV DNA testing in isolated Hepatitis B core positive participants was to be done. Text to clarify that body temperature should be taken orally, removed text regarding the collection of serum samples for the assessment of safety biomarkers during infusion, hypersensitivity, and anaphylactic reactions and text to clarify corticosteroid tapering due to decreased SLE activity after Day 85. Changes in flow cytometry sample collection due to extension of the follow-up period from 90 to 180 days. An additional Clinical Evaluation Questionnaire (CEQ) assessment was to be performed. Amended to include only 200 participants would participate in sample collection for acute phase reactants/biomarkers, all flow cytometry data would remain blinded until the end of the study, and only plasma samples were to be collected for optional biomarker repository samples. To characterize proteomic sample collection, to characterize IFN bioassay sample collection, to reflect the new estimated volume of blood that was to be collected. To clarify that skin photographs would not be obtained from participants who did not present with active skin disease at screening or day 1, to define and describe the method of collection for Adverse Events of Interest (AESIs), sulfasalazine to the list of restricted medications.
28 August 2012	The overall reason for the amendment was to include the following changes: Change in description of sifalimumab dosing, text to reduce overall sample size from 544 participants to 400 participants based on a 20 percent (%) improvement of sifalimumab over placebo in the SRI. Participants were in screening at the time of the 400th subject was randomized, if eligible participants would have been allowed to be randomized into the study. Change in serum sample collection time points. The number of diagnostic test-positive participants per treatment group was revised to 60 participants and the minimum detectable difference was also revised.
23 January 2013	The overall reason for the amendment was to include the following changes: To describe an unblinded interim analysis was planned for the study, which was performed by a limited number of sponsor personnel. To describe the collection of optional urine biomarker samples from eligible participants. To describe that Farr assay testing was to be performed on Day 169. Sample size of diagnostic test-positive participants per treatment group was increased from 60 to 80.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported